BACKGROUND To date, no prospective, multicenter, independently-adjudicated study has evaluated the effectiveness
T he incidence of peripheral arterial disease (PAD) is continuing to grow worldwide, resulting in increasing requirements for treatment and increasing healthcare costs (1, 2) . In 2010, 202 million people were living with PAD globally, an estimated 23.5% increase over the previous decade (1) . In 2001, the estimated cost of PAD in the United States was $4.37 billion (3) . Diabetes mellitus, the most prevalent risk factor for PAD, currently affects 371 million people worldwide, and the incidence is predicted to reach 552 million by 2030 (4, 5) .
PAD now affects 1 in 3 patients with diabetes (6) . Diabetic patients with PAD remain a challenge to treat. Previous studies have shown a decrease in primary and secondary patency following surgical bypass and endovascular interventions in patients with diabetes compared with those without diabetes (7) (8) (9) (10) .
Results of treatment with directional atherectomy (DA), a modality designed to precisely remove the obstructing arterial atheroma, have been reported in multiple single-center and retrospective studies (11) (12) (13) (14) (15) (16) (17) (18) . Patency rates at 12 months varied widely from 54% to 84% depending on patient and lesion characteristics, including recurrent stenosis, method of follow-up, study definitions, and use of a core laboratory for independent evaluation. Previous PAD studies have shown a 10% to 15% decrease in the patency rate when independently adjudicated by a core laboratory compared with investigator-reported patencies (19) . patency rates reported in this paper. Clinically-driven revascularization was defined and monitored by the CEC as reintervention due to $50% diameter stenosis in the presence of recurrent symptoms or an asymptomatic $70% stenosis in the treated segment.
DEFINITIVE LE (Determination of
A pre-specified hypothesis postulated that DA treatment of claudicants with diabetes would have noninferior primary patency at 12 months compared with subjects without diabetes. Previous single-center data evaluated the effectiveness of DA and revealed a primary patency of 67% at 12 months in subjects with claudication. In this study, diabetic subjects had a 12-month primary patency of 60% and nondiabetic subjects had a 12-month primary patency of 68% (14) . In the DEFINITIVE LE study, the sample size required to McKinsey et al.
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work was 60% in each subgroup, resulting in a minimal sample size of 424 claudicant subjects. The overall study was planned to evaluate both claudicants and subjects with CLI with anticipated enrollment of 600
claudicants and 200 subjects with CLI. This sample size ensured that there would be adequate enrollment for the diabetic versus nondiabetic subset analysis.
The primary endpoint for subjects with CLI (RC 4 to 6) was freedom from major unplanned amputation of the target limb through 12 months. Major amputation was defined as amputation above the metatarsal region that was unanticipated before the index procedure. Has in-stent restenosis of the target lesion.
Has an aneurysmal target vessel Has significant stenosis or occlusion of inflow tract that has not been revascularized before treatment of the target vessel
Has perforation, dissection, or other injury of the access or target vessel requiring additional stenting or surgical intervention before enrollment
McKinsey et al.
All subjects underwent revascularization of target Values are mean AE SD (N) or % (n/N).
CABG ¼ coronary artery bypass graft; CLD ¼ claudicants; CLI ¼ critical limb ischemia; PCI ¼ percutaneous coronary intervention. Values are % (n/N) or mean AE SD (N).
SFA ¼ superficial femoral artery; other abbreviations as in Table 2 .
A U G U S T 2 0 1 4 : 9 2 3 -3 3 subjects without tissue loss [baseline RC 1 to 4]), EQ-5D
questionnaire, ABI, and adverse event evaluations. In addition, subjects with a RC of 5 and 6 at baseline had wound assessments at each follow-up visit, including an additional visit at 3 months. Wounds were classified using the Wagner Classification System. All target lesions were analyzed as identified by the angiographic core laboratory.
All statistical analyses were performed using SAS 
Values are % (n).
PTA ¼ percutaneous transluminal angioplasty; other abbreviations as in Table 2 . Values are median (interquartile range) [n], % (n), or mean AE SD (n). *Lesion level characteristics.
Abbreviations as in Table 2 . Table 2) . One subject's data were excluded from all analyses due to an invalid informed consent, yielding a cohort of 799 analyzable subjects.
A total of 1,022 target lesions were treated, the mean longest lesion per patient was 8.3 AE 5.5 cm, 28%
had a lesion length >10 cm, and 21% were total occlusions ( Table 3) . Although the most proximal aspect of target lesions was used to identify lesion location, At investigator discretion, 20% of lesions that had <30% residual stenosis after DA (per core laboratory assessment) still underwent adjunctive PTA. CI ¼ confidence interval.
FIGURE 2 Patency Outcomes: Diabetic Versus Nondiabetic Claudicants
Kaplan-Meier estimates of patency (peak systolic velocity ratio #2.4) by lesion. CI ¼ confidence interval.
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The adjunctive stent rate was 3.2%, including a 1.9% stent rate to treat a perforation. The most common periprocedural adverse event was arterial perforation at 5.3% (Table 5) . Perforations Table 2 .
FIGURE 3 Endpoint Outcomes: CLI Cohort
Kaplan-Meier estimates of outcomes in the critical limb ischemia (CLI) cohort.
CI ¼ confidence interval.
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McKinsey et al. to 82.1%] nondiabetic) (noninferiority, p < 0.001; superiority, p ¼ 0.98, using a PSVR #2.4) (Fig. 2) . In moderate-length lesions (5.0 to 9.9 cm), patency rates were 83% in the SFA, 74% in the poplitealartery, and 88% in the infrapopliteal artery. The patency rates in longer lesions ($10 cm) were 65% in the SFA and popliteal arteries. Patency was 88% to 91% for infrapopliteal lesions irrespective of length (Table 6 ). Secondary 12-month patency among claudicants was 89% overall.
The primary endpoint of CLI subjects at 12 months (freedom from target limb major amputation) was DA ¼ directional atherectomy; PSVR ¼ peak systolic velocity ratio; RCT ¼ randomized controlled trial. 95% (95% CI: 90.7% to 97.4%). Duplex-determined primary patency in all CLI lesions, a pre-specified secondary endpoint, was 71% (95% CI: 64.6% to 76.5%) and secondary patency was 88% (95% CI:
82.9% to 92.1%) (Fig. 3, Table 6 ). Target lesion location patency at 12 months in CLI subjects was as follows:
SFA, 68%; popliteal artery, 67%; and infrapopliteal artery, 78%. The patency rate in the CTO lesions was 63.3% in the claudicants (mean lesion length, 11.2 cm) and 65.5% in the CLI cohort, with a mean length of Table 7) .
DISCUSSION
The DEFINITIVE LE study objectively evaluated, with independent core laboratory and CEC adjudication, the acute safety and 12-month durability of DA in the treatment of infrainguinal PAD in claudicants and CLI subjects. This study demonstrated effective debulking to #30% diameter stenosis in lesions up to 20 cm in length using DA with selective adjunctive PTA. Stent placement rate was a very low 3.2%, dramatically lower than the 40% to 50% bail-out rates reported in the PTA arms of recent stent studies (20, 21) . Critically, the patency rates observed in DEFINITIVE LE are similar to the rates published in SFA studies of second-generation nitinol stents (Table 8) . Although direct comparisons cannot be made given the heterogeneity of the subjects studied across all protocols, the DEFINITIVE LE study demonstrates that DA has results comparable to those of other contemporary technologies treating infrainguinal PAD but with the distinct advantage of rarely leaving a permanent implant in place. The DEFINITIVE LE study was not limited to a specific lesion or subset of lesions, and, as such, it is able to provide scientific information across many anatomic locations and subject subsets.
Lesion length is a predictor of long-term patency for most endovascular therapies (20) (21) (22) . In the DEFINITIVE LE study, the mean lesion length was 7.5 cm, the longest mean lesion was 8. . This group treated 30 subjects with severe calcification with DA followed by a DCB. Bail-out stents were necessary in only 2 subjects (6.5%), and the primary patency rate at 1 year was 90%.
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A unique attribute of the DEFINITIVE LE study design was the pre-specified noninferiority hypothesis for 12-month patency of diabetic to nondiabetic subjects, which was met (77% vs. 78%; noninferiority, The DEFINITIVE LE study has confirmed the safety in treatment of subjects with single-level to multilevel lower extremity disease and confirmed the durability of DA across a broad spectrum of subjects.
Indeed, the ability to treat multilevel disease with a single device and to have an adjunctive stent rate just over 3% and a patency rate consistent with rates of previous primary stent trials indicates that DA is a very effective therapy for patients with PAD who present with either claudication or CLI. 
CONCLUSIONS
The DEFINITIVE LE study confirmed that DA is a safe and effective treatment modality through 12 months for patients with claudication and CLI. 
